Valuation: Theraclion

Market Cap 48.18M 55.07M 44.43M 41.11M 78.02M 5.26B 79.33M 532M 209M 2.58B 207M 202M 8.94B P/E 2024
-2.66x
P/E 2025 -6.33x
Enterprise Value 56.03M 64.05M 51.67M 47.81M 90.74M 6.11B 92.26M 619M 243M 3B 240M 235M 10.4B EV / Sales 2024
22.5x
EV / Sales 2025 55.4x
Free-Float
54.37%
Yield 2024 *
-
Yield 2025 -
1 day+1.67%
1 week+2.45%
Current month+6.69%
1 month-8.22%
3 months+41.65%
6 months+9.84%
Current year+11.30%
1 week 0.62
Extreme 0.621
0.69
1 month 0.6
Extreme 0.605
0.8
Current year 0.4
Extreme 0.402
0.93
1 year 0.33
Extreme 0.33
1.25
3 years 0.14
Extreme 0.1416
1.25
5 years 0.14
Extreme 0.1416
2.22
10 years 0.14
Extreme 0.1416
7.78
Manager TitleAgeSince
Chief Executive Officer - 23/05/2023
Director of Finance/CFO - -
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member - 31/01/2018
Director/Board Member - 12/02/2019
Director/Board Member - 12/02/2019
Date Insider Type Main position Quantity % Market Cap.
06-07Sell

Director

-25,000 0.0342%
Change 5-day change 1-year change 3-year change Capi.($)
+1.67%+2.45%+91.43%+11.67% 54.93M
+2.12%-0.33%+24.25%+0.94% 190B
-0.87%-3.18%-21.90%+21.22% 147B
+1.94%-1.55%-3.04%-16.89% 135B
-0.19%-0.69%-56.46%-14.93% 66.6B
-2.35%-2.99%+18.60%-0.10% 53.92B
+0.38%-1.66%-27.47%-30.84% 43.57B
+2.10%+0.80%+8.60%+11.30% 36.45B
+2.15%-0.66%+7.90%+42.37% 36.15B
+0.47%-1.31%-19.18%-4.49% 29.69B
Average +0.77%+0.88%+2.27%+2.02% 73.8B
Weighted average by Cap. +0.80%+1.62%-4.00%+0.65%

Financials

2024 2025
Net sales 830K 949K 766K 708K 1.34M 90.59M 1.37M 9.17M 3.59M 44.48M 3.56M 3.49M 154M 652K 745K 601K 556K 1.06M 71.14M 1.07M 7.2M 2.82M 34.94M 2.8M 2.74M 121M
Net income -5.76M -6.58M -5.31M -4.91M -9.32M -628M -9.48M -63.58M -24.92M -308M -24.71M -24.17M -1.07B -5.69M -6.5M -5.25M -4.85M -9.21M -621M -9.37M -62.84M -24.63M -305M -24.42M -23.89M -1.06B
Net Debt 3.41M 3.9M 3.15M 2.91M 5.52M 372M 5.62M 37.67M 14.77M 183M 14.64M 14.32M 633M 7.85M 8.98M 7.24M 6.7M 12.72M 857M 12.93M 86.71M 33.99M 421M 33.7M 32.97M 1.46B
Logo Theraclion
Theraclion specializes in developping, manufacturing and marketing echotherapy equipment associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules.Net sales break down by activity as follows: - sale of consumables (52.8%); - sale of equipment (28.8%); - provision of after-sales services (18.4%). The vast majority of net sales are earned abroad.
Employees
36
Date Price Change Volume
09/07/26 0.6700 +1.67% 17,476
08/07/26 €0.6590 -1.64% 41,279
07/07/26 €0.6700 -2.33% 66,216
06/07/26 €0.6860 +10.47% 132,195
03/07/26 €0.6210 -5.05% 65,368

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALTHE Stock